 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | STRO-001 / Sutro Biopharma
Enrollment change, Trial completion date, Trial termination, Metastases: Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies (clinicaltrials.gov) - Feb 21, 2024
P1/2, N=9, Terminated, Sponsor: BioNova Pharmaceuticals (Shanghai) LTD.
N=50 --> 9 | Trial completion date: Dec 2024 --> Dec 2023 | Recruiting --> Terminated; Due to company decision
- || STRO-001 / Sutro Biopharma
Enrollment open, Metastases: Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies (clinicaltrials.gov) - Mar 24, 2023
P1/2, N=50, Recruiting, Sponsor: BioNova Pharmaceuticals (Shanghai) LTD.
N=50 --> 9 | Trial completion date: Dec 2024 --> Dec 2023 | Recruiting --> Terminated; Due to company decision Not yet recruiting --> Recruiting
- | STRO-001 / Sutro Biopharma
Journal: Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001. (Pubmed Central) - Jan 13, 2023
In MCL Mino and Jeko-1 xenografts, STRO-001 starting at 3 mg/kg significantly prolonged survival or induced tumor regression, respectively, leading to tumor eradication in both models. In summary, high CD74 expression levels in tumors, nanomolar cellular potency, and significant anti-tumor in DLBCL and MCL xenograft models support the ongoing clinical study of STRO-001 in patients with B-cell NHL.
- | STRO-001 / Sutro Biopharma
Preclinical, Journal: Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemia. (Pubmed Central) - Jan 4, 2023
In summary, high CD74 expression levels in tumors, nanomolar cellular potency, and significant anti-tumor in DLBCL and MCL xenograft models support the ongoing clinical study of STRO-001 in patients with B-cell NHL. No abstract available
- || STRO-001 / Sutro Biopharma
Enrollment closed, Enrollment change, Metastases: Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies (clinicaltrials.gov) - Dec 14, 2022
P1, N=70, Active, not recruiting, Sponsor: Sutro Biopharma, Inc.
No abstract available Recruiting --> Active, not recruiting | N=220 --> 70
- STRO-002 / Sutro Biopharma
Pediatric Acute Myeloid Leukemia with Co-Occurring BCR::ABL and CBFA2T3::GLIS2 Dual Fusion with Deep Response to FOLR1-Targeting Antibody Drug Conjugate Stro-002 and Tyrosine Kinase Inhibitor () - Nov 29, 2022 - Abstract #ASH2022ASH_7278;
Due to lack of response to AML therapy at end of Induction (EOI) I, she was taken off protocol and started on modified ALL regimen for Induction II consisting of cytarabine, low dose weekly methotrexate and bimonthly peg-asparaginase with addition of an oral TKI, dasatinib...Given availability of FOLR1 directed ADC on single-patient compassionate use basis, patient received single agent STRO-001 on a bi-monthly basis...Long-term follow-up is required to assess durability of remission. Additional testing of this approach in a larger patient population is needed to determine the role of STRO-002 in this high-risk pediatric AML population.
- || STRO-001 / Sutro Biopharma
New P1/2 trial, Metastases: Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies (clinicaltrials.gov) - Nov 10, 2022
P1/2, N=50, Not yet recruiting, Sponsor: BioNova Pharmaceuticals (Shanghai) LTD.
- || STRO-001 / Sutro Biopharma
Trial primary completion date, Metastases: Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies (clinicaltrials.gov) - Aug 3, 2022
P1, N=220, Recruiting, Sponsor: Sutro Biopharma, Inc.
Additional testing of this approach in a larger patient population is needed to determine the role of STRO-002 in this high-risk pediatric AML population. Trial primary completion date: Nov 2021 --> Nov 2022
- STRO-001 / Sutro Biopharma
Therapeutic Targeting of CD74 with STRO-001 Antibody-Drug Conjugate in AML and ALL (GWCC - B213-B214, Level 2) - Nov 5, 2021 - Abstract #ASH2021ASH_1940;
Through transcriptomics profiling and validation of the cell surface expression by flow cytometry, we have identified CD74 as a viable therapeutic target for AML and ALL in children and adults. We further demonstrate that targeting CD74 with STRO-001 effectively eliminates leukemia cells both in vitro and in vivo , providing the preclinical data to compel evaluation of STRO-001 in clinical trials for childhood and adult leukemia.
- | Xalkori (crizotinib) / Pfizer, STRO-001 / Sutro Biopharma
Journal: Aberrant Expression of and Cell Death Induction by Engagement of the MHC-II Chaperone CD74 in Anaplastic Large Cell Lymphoma (ALCL). (Pubmed Central) - Oct 14, 2021
Finally, we demonstrate that the CD74-targeting antibody-drug conjugate STRO-001 efficiently and specifically kills CD74-positive ALCL cell lines in vitro. Taken together, these findings enabled us to demonstrate aberrant CD74-expression in ALCL cells, which might serve as tool for the development of new treatment strategies for this lymphoma entity.
- STRO-001 / Sutro
[VIRTUAL] Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_3828;
P1
STRO-001 has been well-tolerated. No ocular or neuropathy toxicity signals have been observed and the MTD has not been reached.
- | STRO-001 / Sutro Biopharma
Enrollment open, Metastases: Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies (clinicaltrials.gov) - Feb 26, 2018
P1, N=220, Recruiting, Sponsor: Sutro Biopharma, Inc.
No ocular or neuropathy toxicity signals have been observed and the MTD has not been reached. Not yet recruiting --> Recruiting
- | STRO-001 / Sutro Biopharma
New P1 trial, Metastases: Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies (clinicaltrials.gov) - Feb 7, 2018
P1, N=220, Not yet recruiting, Sponsor: Sutro Biopharma, Inc.